FDA Brief

Warning letters Drugs

FDA warning letter to

Refills Health, LLC dba Refills Health

MediumIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.

What happened

FDA reviewed the company's website at https://www.refills.com in December 2025 and found it offering compounded drug products, including semaglutide, a diabetes and weight-loss medicine. The site's pictured labels name "Refills Health," which suggests the company compounded the drugs when FDA says it did not. The site also called the products "clinically proven" and said they contain "the same active ingredient found in certain FDA approved treatments," even though compounded drugs are not FDA-approved.

What FDA found

  1. Website labels show "Refills Health" on the product label, which tells buyers the company made the drug when it did not, making the labeling false or misleading (misbranded).

    FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)
  2. Advertising claims for a compounded drug that are false or misleading also make the drug misbranded.

    FDCA § 502(bb) [21 U.S.C. § 352(bb)]
  3. Calling the products "clinically proven" implies FDA approval or a safety and effectiveness review that never happened.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. Saying the products contain "the same active ingredient found in certain FDA approved treatments" suggests the compounded drugs are FDA-approved when they are not.

    FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  5. These compounded products are "new drugs" not generally recognized as safe and effective, so they must meet the conditions in section 503A or 503B to be exempt from approval requirements.

    FDCA §§ 201(p), 503A, 503B [21 U.S.C. §§ 321(p), 353a, 353b]
  6. Shipping misbranded drugs, and receiving or delivering them in interstate commerce, is a prohibited act.

    FDCA §§ 301(a), 301(c) [21 U.S.C. §§ 331(a), 331(c)]

What FDA wants

Within 15 working days the company must send CDER's Office of Compounding Quality and Compliance a written response describing the steps taken to fix the violations and prevent them from recurring. FDA specifically asks the company to identify who actually makes the compounded products, supply sample labeling, and fix or remove the misleading website claims.

Who should pay attention

  • telehealth platforms selling compounded semaglutide and other GLP-1 drugs
  • compounding pharmacies whose products are resold or marketed under another company's name
  • marketing and affiliate teams writing drug claims for online pharmacy sites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  3. FitRX, LLC dba Zealthy

    FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.

    Medium
  4. ybycmeds

    FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.

    Medium